Brain dopamine receptors appear to play a major role in the control of many diseases of the central nervous system (CNS), including schizophrenia. Drugs developed on the basis of dopamine hypothesis had beneficial effects, but did not cure schizophrenia or control the cognitive domain of the disease. The search for new appoaches to the treatment of psychosis led to the hypothesis that glutamate receptors may be involved in the pathogenesis of some psychiatric diseases. Dr. Darryle Schoepp, Merck & Co, strongly supported this approach. In a videointerview with Dr. Greg Rose (see below) Dr. Darryle Schoepp discusses possible role of glutamate receptors in schizophrenia and proposes the development of glutamate agonists for treatment of psychosis.
Keywords: CNS diseases; schizophrenia, psychosis, dopamine receptors, glutamate receptors, cognition domain, glutamate agonists, Dr. Darryle Schoepp; Merck & Co.; Dr. Greg Rose.
No comments:
Post a Comment